INVESTIGATION OF CLINICAL AND HORMONAL EFFECTS OF GHRP, GHRH, AND 1485 PLUS GHRH

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。研究表明，GHRH对身材矮小的儿童的生长速度和生长激素水平有持续的积极作用，甚至在停止使用GHRH后也有长期的影响，这表明GHRH有可能恢复生长激素的分泌。其他涉及老年男性慢性给予14天GHRH的研究表明，GHRH可以逆转GH和IGF水平的下降。已经开发了几种称为生长激素释放肽的合成肽。已经发现ghrp在多种动物体内释放生长激素。GHRP通过非阿片类、非ghrh受体对下丘脑和垂体的作用特异性释放GH。据推测，GHRP的活性反映了一种特定的内源性激素和受体的活性。当与GHRH联合使用时，GHRP非常协同地释放GH。GHRP-1已在正常男性和女性中进行测试，未发现实验室或临床不良反应。GHRP-2现已长期应用于正常青年男女、老年受试者、儿童和垂体瘤患者。本研究将单独研究另一种GHRP 1485的剂量反应效应，并与GHRH联合研究1485的疗效和安全性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Studies have shown the sustained positive effect of GHRH on growth rate and GH levels in short stature children and demonstrated a prolonged effect even after discontinuing GHRH which indicates it may be possible to restore GH secretion with GHRH. Other studies involving chronic administration of GHRH for fourteen days in elderly men showed that GHRH can reverse decreased GH and IGF levels. Several synthetic peptides, called Growth Hormone Releasing Peptides, have been developed. GHRPs have been found to release GH in a variety of animals. GHRP specifically releases GH by an action on the hypothalamus and pituitary via non-opiate, non-GHRH receptors. It is hypothesized that the activity of GHRP reflects the activity of a specific endogenous hormone and receptor. When used in combination with GHRH, GHRP very synergistically releases GH. GHRP-1 has been tested in normal men and women and revealed no laboratory or clinical adverse effects. GHRP-2 has now been given chronically to normal young men and women, elderly subjects, children and patients with pituitary tumors. In this study, the dose response effect iv, sc, and orally of 1485, another GHRP, will be studied alone and in combination with GHRH to measure efficacy and safety.